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ABSTRACT
INTRODUCTION
Depression is a very common and major health problem, with 350 million people affected globally. 
Several treatments are available for depression including pharmacological and psychosocial, but for 
moderate to severe depression in adults, clinical guidelines recommend antidepressants as the first 
line of treatment for adults. Randomised controlled trials provide the best evidence on the 
comparative effectiveness of antidepressants for depression, but are limited by a short follow-up 
and a highly selected population. To understand whether the effects obtained in clinical trials are 
similar to the effects seen in daily clinical practice, we need information collected in primary care 
where the majority of patients with depression are prescribed antidepressants and are followed up.  
We aim to conduct a cohort study on a large database to assess acceptability, efficacy, safety and 
tolerability of antidepressant monotherapy in people with depressive disorder in primary care.
METHODS AND ANALYSIS
We will conduct a cohort study using data from the QResearch primary care research database, 
which is the largest general practice research database in the UK.
We will include a cohort of patients registered for at least one year from 1st Jan 1998, diagnosed 
with a new episode of depression and on antidepressant monotherapy and a comparison group 
with depression not on antidepressant treatment. 
The exposure of interest will be treatment with antidepressant medications, which will include 
tricyclics, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, and other 
antidepressants. 
Our outcomes will be acceptability (in terms of treatment discontinuation due to any cause), 
efficacy (in terms of clinical response and remission); safety (in terms of adverse events and all-
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3
cause mortality); and tolerability (in terms of dropouts due to any adverse event) all measured at 
2 months, 6 months and one year.
For each outcome, we will estimate the absolute risks for all antidepressants, and also for each 
individual drug separately, for each time point of interest. We will also estimate relative effects 
between antidepressants using Cox’s proportion hazards models. We will calculate hazard ratios 
(HRs) and 99.9% confidence intervals (CIs) for each outcome of interest.  
DISCUSSION
Our study will examine the effectiveness and safety of antidepressant monotherapy in a real-
world setting.
The main limitation is the observational nature of our study, while the major strengths include the 
large representative population contained in QResearch and the possibly high generalisability. 
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INTRODUCTION
Depression is a very common major health problem, 350 million people in the world are affected.[1] 
There are several effective treatments for depression including drug treatment and talking 
therapies,[2] but clinical guidelines often recommend antidepressant medications as the first 
method of treatment for adults with moderate to severe depression.[3,4,5] Antidepressants are 
very commonly used (in England alone, 64.7m prescriptions for antidepressants were dispensed in 
2016). After two months of treatment, an average 26.4% of patients discontinue antidepressants 
due to any cause, while an average of 10.4% of patients discontinue antidepressants for side-effects 
that cannot be tolerated.[6] This might happen because antidepressants are prescribed without a 
clear understanding of which drug is the most appropriate medication for each patient taking into 
account their characteristics, so people often stop the antidepressant early because they are 
prescribed a drug which might work for the “average person” but has not been tailored to them 
individually.[7] Clinical trials provide the best evidence regarding average comparative efficacy of 
drugs, but they are usually not designed to assess adverse events, especially if they are rare or less 
common. In addition, their external validity is limited because they focus on treatments over short 
periods of time (usually 8-12 weeks) in highly selected patients rather than in more complicated, 
real-world cases, such as patients with multiple co-morbidities and concurrent long-term 
medication that are seen in routine practice by general practitioners (GPs). To understand the 
effects of antidepressants in real world conditions, we aim to conduct a cohort study using a large 
and representative sample from primary care in England, to assess acceptability, efficacy, safety and 
tolerability of antidepressants in adults with depression.
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METHODS
Setting
We will undertake the study using data from the QResearch primary care research registry 
(www.qresearch.org). This registry is the largest general practice research database in the UK, and 
it contains in total the anonymised electronic healthcare records of over 35 million patients ever 
registered with 7,500 general practices throughout UK.[8] Consent to provide data for QResearch 
was sought from all UK practices using the Egton Medical Information Systems (EMIS) medical 
records system. EMIS is the major supplier of primary care computer systems in the UK and is in use 
in two-thirds of all UK general practices. 
The information recorded on the QResearch database includes patient demographic data (year of 
birth, gender, socio-economic data), characteristics (height, weight, smoking status), symptoms, 
clinical diagnoses, consultations, referrals, prescribed medications and results of investigations. The 
latest version of the QResearch database, which is updated quarterly, will be used for the analysis.  
Detailed analyses have compared QResearch practices with all UK practices and found that practices 
contributing to QResearch are somewhat larger than UK practices overall but are very similar in 
other respects (e.g. age-sex distribution and prevalence of chronic diseases).[8] Within QResearch, 
we will use data coming from English general practices.
Population
We will initially identify an open cohort of patients aged 18-100 years at the study entry date drawn 
from patients registered with eligible practices since 1st Jan 1998. Patients will be included if they 
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have been registered with the practice for at least 12 months. Patients will be followed up for 12 
months.
We will use Read codes to identify patients with a diagnosis of depression, using as a starting point, 
case definitions that have been used in previous studies.[9,10] We will exclude:
- patients with a recorded diagnosis of bipolar disorder or schizophrenia spectrum disorder;
- patients with a diagnosis of post-partum depression made within 180 days before or up to 
180 days after the first diagnosis of depression;
- patients prescribed more than one antidepressant at baseline;
- patients prescribed antipsychotics or mood stabilisers; 
- patients if they had received prescriptions for an antidepressant or they had a diagnosis of 
depression before their entry date in the cohort;
- patients with a diagnosis of depression made two months before or two months after 
starting an antidepressant.
Our final cohort for analysis will include exposed groups of patients on each antidepressant 
monotherapy, and an unexposed group of patients not on antidepressants.
Drug Exposure
The primary exposure of interest is the use of licensed antidepressants, which will be considered 
individually and also grouped according to the four main classes in the British National Formulary 
(BNF) (https://bnf.nice.org.uk). The groups will consist of tricyclics (TCAs) (i.e. amitriptyline, 
amoxapine, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, iprindole, 
lofepramine, maprotiline, mianserin, nortriptyline, protriptyline, trimipramine, viloxazine), selective 
serotonin reuptake inhibitors (SSRIs) (i.e. citalopram, escitalopram, fluoxetine, fluvoxamine, 
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paroxetine, sertraline), monoamine oxidase inhibitors (MAOIs) (i.e. isocarboxazid,  moclobemide, 
phenelzine, tranylcypromine) and other antidepressants (i.e. agomelatine, duloxetine, mirtazapine, 
nefazodone, reboxetine, tryptophan, trazodone, venlafaxine, vortioxetine).[11]
Information will be extracted from all prescriptions for antidepressants issued during 12-months 
follow-up.  We will calculate the duration of each prescription in days by dividing the number of 
tablets prescribed by the number of tablets to be taken each day. If the information on tablets per 
day is missing or not sufficiently detailed (expected to be < 5% of total prescriptions) we will 
estimate the duration of the prescription based on the number of tablets prescribed, as in previous 
studies.[10] Patients will be classified as continually exposed to an antidepressant during periods 
where there were no gaps of more than 30 days between the end of one prescription and the start 
of the next. Patients will be also classified as exposed for the first 30 days after the estimated date 
of stopping an antidepressant in order to account for any delays in starting the prescription or 
accumulation of tablets as well as to attribute the outcomes occurring during withdrawal periods to 
the antidepressant, as done in previous studies.[10] The daily dose of each prescription will be 
calculated by multiplying the number of tablets to be taken each day by the dose of each tablet, and 
then converted to a defined daily dose using values assigned by the World Health Organization’s 
Collaborating Centre for Drug Statistics Methodology (www.whocc.no/atc_ddd_index).
Outcomes
We will measure the following outcomes up to two months, six months and one ear from the initial 
prescription of antidepressants or from the date of the first episode of depression for patients not 
on antidepressants.
Primary outcomes
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1) Acceptability of treatment will be measured as all cause treatment dropout rate.
Treatment dropout will be computed if:
 - A patient has a gap of more than 30 days between the end of a prescription of an antidepressant 
and the start of the next prescription, or
- a patient switches to another antidepressant, or
 - a patient is prescribed a new antidepressant, a mood stabiliser, or an antipsychotic.
2) Tolerability of treatment, measured as treatment dropout (measured as described above) after 
any adverse event occurred (i.e. no subsequent prescriptions or implementation of a 
switch/combination/augmentation strategy after the occurring of an adverse event). The list of 
adverse events is described below.
Secondary outcomes
3) Safety, measured as:
 number of patients with at least one adverse event (AE) among the ones specified below, 
independently of whether the patients did drop out or not. We will use the Read codes for 
adverse events that have been shown in randomised trials as the frequent and severe 
adverse events of antidepressant. These include: nausea, headache, dry mouth, insomnia, 
dizziness, sedation/somnolence, diarrhoea, constipation, sexual dysfunction, fatigue, 
rhinitis/ nasopharyngitis, hyperhidrosis, respiratory disorder (infection, cough), anxiety, 
decreased or increased appetite, tremor, pain, vomiting, abdominal pain/discomfort, 
dyspepsia, agitation, visual impairment, ejaculation disorder/erectile dysfunction, weight 
increased or decreased, blood pressure increased, arrhythmia/heart rate disorder, abnormal 
dreams, infection, blood pressure increased or decreased, extrapyramidal disorders, suicidal 
ideation/behaviour or self-harm, hot flush, dysuria, skin disorder, flatulence, urinary 
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disorders, injury, yawning, eye disorders, paraesthesia, nervous system symptoms, feeling 
cold, menstrual disorder, chest pain, disturbance in attention, libido increased, psychiatric 
symptoms, fall, confusional state, salivary hypersecretion, accidental overdose, 
cardiovascular symptoms (e.g. angina), sleep disturbance, oedema, aggression, completed 
suicide, affect lability, fever, euphoric mood, hypersomnia, memory impairment, muscular 
skeletal problems, serotonin syndrome, withdrawal syndrome).
 All-cause mortality. Patients who have died will be identified using death data recorded on 
the patients’ general practice record as in previous studies.[10,12] 
4) Efficacy, measured at the last observation before 2, 6 and 12 months, as:
 Clinical remission, measured as scoring less than a prespecified threshold on a standardised 
rating scale,[6] such as the Hamilton Depression Rating Scale (HDRS), the Montgomery and 
Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Patient 
Health Questionnaire (PHQ-9), the Geriatric Depression Scale (GDS) (e.g. a score < 7 for the 
HDRS would be considered as remission).  
 Clinical response to antidepressant treatment, measured as 50% reduction on a 
standardised rating scale, compared with the most recent value recorded in the 6 months 
before the first antidepressant prescription.
Confounder variables
Confounders will include baseline variables that we consider to be potential risk factors for the 
outcomes and are also potentially associated with the likelihood of receiving a particular 
antidepressant treatment, based on previous studies of antidepressants.[9] These include:
 age at study entry, in years;
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10
 sex; 
 year of diagnosis of depression;
 type of diagnosis (major depressive disorders, minor depression, other);
 severity of index diagnosis of depression (categorised as mild, moderate or severe, using the 
Read codes published by Martinez et al.;[13] 
 deprivation (Townsend deprivation score corresponding to the patients postcode, in 
fifths);[14] 
 smoking status (non-smoker, ex-smoker, light smoker: 1–9 cigarettes/day, moderate 
smoker: 10–19 cigarettes/day, heavy smoker: P 20 cigarettes/day, not recorded); 
 alcohol intake (none, trivial: < 1 unit/day, light: 1–2 units/day, medium: 3–6 units/day, 
heavy: 7–9 units/day, very heavy: > 9 units/day, not recorded); 
 ethnic group (categorised as either white/not recorded or non-white [Indian, Pakistani, 
Bangladeshi, other Asian, black African, black Caribbean, Chinese, other including mixed]); 
 comorbidities at baseline (binary variables for each of coronary heart disease, stroke/ 
transient ischaemic attack, diabetes, hypertension, cancer, epilepsy/seizures, 
hypothyroidism, osteoarthritis, rheumatoid arthritis, suicidal ideation/behaviour or self-
harm, obesity, asthma/chronic obstructive airways disease, osteoporosis, liver disease, renal 
disease, obsessive-compulsive disorder); and 
 use of other drugs at baseline (binary variables for each of anticonvulsants, hypnotics/ 
anxiolytics, antihypertensive drugs, aspirin, statins, anticoagulants, non-steroidal anti-
inflammatory drugs, bisphosphonates, oral contraceptives, hormone replacement therapy.   
Handling of missing data
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Excluding subjects with missing values would reduce the sample study size, thus decreasing 
precision and power.[15] We will use multiple imputation by chained equations to impute values 
when actual values are not available. We will fill in missing data using the multiple imputation by 
chained equations (MICE) procedure. We will first analyse the pattern of distribution of missing 
values in order to assess if the data are suitable for multiple imputation using chained equations. 
For each imputation we will generate ten imputed datasets and we will combine coefficient 
estimates across these using Rubin’s rules.[16] We will include all of the confounding variables in 
the multiple imputation process, along with the outcome variable as it carries information about 
predictors’ missing values.
Statistical analysis 
We will use Stata MP 16.0 to conduct statistical analysis. We will follow the “REporting of studies 
Conducted using Observational Routinely-collected health Data” (RECORD) Statement.[17] 
Descriptive statistics 
We will split the population into antidepressant users and non-users.
In the study cohort of patients with a diagnosis of depression we will summarise baseline 
characteristics with descriptive statistics and will describe patterns of antidepressant use according 
to type of antidepressant prescribed, duration of use and dose. We will describe the severity of 
depression (classified as mild, moderate or severe) in the study cohort, overall and by age and 
gender. We will describe patterns of antidepressant use according to severity of depression. 
Time to event analysis
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We will determine absolute and relative risks according to type of antidepressant prescribed for 
dropouts due to any cause (acceptability), dropouts due to any adverse event (tolerability), 
response and remission (efficacy), patients experiencing adverse events and all-cause mortality 
(safety). 
Incidence rates of all the outcomes above described will be calculated in the study cohort of 
people with a new diagnosis of depression. The statistical analysis will comprise a series of survival 
analyses to assess the relationship between exposure to each antidepressant monotherapy (and 
antidepressants grouped according to the four main classes in the BNF) and acceptability, efficacy, 
safety and tolerability. Dose of an idepressant drugs will be examined in the analyses. The date of 
entry into the survival analyses will be the date of starting an antidepressant for patients on 
antidepressants and the date of the first episode of depression for patients not on 
antidepressants. The right censor date will be the earliest of the following: date of dropout, date 
of switch to another antidepressant, date of a new antidepressant added, date of a mood 
stabiliser added, date of an antipsychotic added, date of the outcome of interest, date of death, 
date of leaving the practice, or the study end date. 
We will explore non-linear relationships between continuous variables and the outcome using 
fractional polynomials.[18]
Cox’s proportion hazards models accounting for practice clustering will be used for all time-to-
event analyses. The analyses will calculate hazard ratios (HRs) and 99.9% confidence intervals (CIs) 
comparing: 
1. The risk of acceptability, efficacy, safety and tolerability for each antidepressant will be 
directly compared with each other. 
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2. The risk of efficacy and safety in patients on any type of antidepressant compared with 
patients with no antidepressant treatment. 
3. Each separate class of antidepressants (SSRIs, TCAs, MAOIs and other antidepressants) will 
be directly compared with each other for acceptability, efficacy, safety and tolerability and 
compared with no treatment for efficacy and safety. 
4. Analyses will also calculate HRs according to prescribed dose of antidepressant; where 
numbers are sufficient individual antidepressants within each class will be examined. 
5. Analyses of interaction will be carried out to examine the extent to which patient’s 
characteristics (age, gender), use of other medications and comorbidities modify the 
relationship between antidepressant use and outcomes. 
Adjustment will be made for potential confounders as listed above. The assumptions of the Cox 
proportional hazards model will be checked. In case these assumptions are implausible, we will 
instead employ alternative parametric survival models.  
Self-controlled case-series analysis 
The self-controlled case-series analysis only uses the patients in the cohort who have the 
outcomes of interest.[19] Cases with each type of adverse event will be identified; these will be 
cases with a diagnosis of the adverse event since 1st January 1998, who had a new diagnosis of 
depression (see above for details). Information on prescriptions for antidepressants in these cases 
will be extracted and the analysis (such as conditional fixed-effects Poisson regression model) will 
compare rates of the outcomes of interest in periods following a first prescription for an 
antidepressant compared with a baseline period free of antidepressant treatment for the same 
patient.[20]
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Propensity score
A propensity score for antidepressant use will be calculated using a logistic regression 
model,[21,22] which will initially include all confounders. Antidepressant users will be matched to 
a common comparator (e.g. fluoxetine users) and to non-antidepressant users on the logit of the 
propensity score using a caliper width of 0.2 of the standard deviation of the logit of the 
propensity score. A matching ratio of 1:1 will be used.[23] We will assess standardised differences 
between the two groups with 10% or more considered as suggestive of imbalance.[24] We will 
then perform a multivariable cox regression to estimate the effect of antidepressant on outcome 
occurrence. 
DISCUSSION
This protocol describes a large cohort study which aims to assess the acceptability, efficacy, safety 
and tolerability of antidepressant monotherapy in adults with depressive disorder in primary care.
This study is part of the “Personalise antidepressant treatment for unipolar depression combining 
individual choices, risks and big data (PETRUSHKA)” project. PETRUSHKA seeks to ultimately develop 
and test a precision medicine approach to the pharmacological treatment of major depressive 
disorder by synthesizing data coming from randomized controlled trials (RCTs) and data coming 
from observational studies and patient registries.[25] 
This study builds on a solid foundation of research performed on QResearch on the safety of 
antidepressants use in people aged 20–64 years,[10] and in older people[9] and contributes to the 
field by focusing on clinically relevant outcomes which have been evaluated also in RCTs.
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At present, the best evidence in terms of comparative efficacy and acceptability of antidepressants 
comes from the “Group of Researchers Investigating Specific Efficacy of individuaL Drugs for Acute 
depression (GRISELDA)” study, which was a network meta-analysis including only RCTs.[6] Indeed, 
RCTs are the most reliable source of information on relative treatment effects. However, RCTs have 
strictly experimental settings and employ inclusion criteria which might limit their ability to predict 
results in real-world clinical practice.[26] Large observational studies may complement evidence 
provided by RCTs and potentially address some of their limitations. Recently, Efthimiou et al. [27] 
developed statistical methods for combining randomized and non-randomized evidence in a 
network meta-analysis.[27] 
Our study aims to investigate the effectiveness of antidepressant monotherapy in a real-world 
setting.[28] The study design is a cohort study and thus observational in nature.[29] Compared to 
the GRISELDA study, the outcomes will include an in-depth evaluation of side effects, with a longer 
follow-up (one year).  Moreover, in our cohort study we will include a representative population of 
people with depression in England, also including people with multiple comorbidities, who would 
normally be excluded in a RCT. This is because people with multiple comorbidities represent the 
added value of a real-world study, whose results aim to be generalised to a wide population. 
The major strengths of our study include the large population contained in QResearch and the 
potentially high generalisability (external validity). The main limitation is the weaker internal validity 
of our study when compared to RCTs due to potential indication biases and residual confounding. 
RCTs are generally considered to be at a lower risk of bias compared to observational studies, when 
aiming to estimate causal effects of interventions.[30]
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In the future, we aim to predict the effects of different antidepressants given information on 
patient-level characteristics, by using both statistical and machine learning tools (such as artificial 
neural networks and support vector machines). The present study will identify a range of possible 
prognostic factors and effect modifiers which will be used to inform the predictive model. The 
predictive model will then be used in PETRUSHKA to develop a web-based treatment algorithm to 
help clinicians, patients and carers to personalise the choice of antidepressant in primary care.[25]
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